Skip to main content
. 2022 Dec 9;9:987887. doi: 10.3389/fmed.2022.987887

TABLE 4.

Demographic data and clinical features of study participants in the negative group, suspected group, and CVA positive diagnosis group.

Characteristics and variables Negative group (n = 64) Suspicious group
(n = 34)		 CVA positive diagnosis group (n = 42) P-value
Age (years) 55.00 [24.75] 37.50 [23.25]† 42.00 [29.50] 0.002
Gender, male (n,%) 16 (25.00%) 18 (52.94%) 12 (28.57%) 0.015
Height (cm) 162.00 [9.50] 170.00 [16.25]† 165.00 [14.00] 0.021
Weight (kg) 60.00 [10.50] 64.50 [16.50] 62.00 [19.25] 0.489
BMI (kg/m2) 22.86 [3.38] 22.18 [4.81] 22.81 [4.72] 0.439
Former smoker (n,%) 10(15.62%) 1(2.94%) 4 (9.52%) 0.148
Symptom duration (months) 7.50 [11.00] 6.50 [6.50] 9.50 [9.50] 0.21
Symptom recovery time (days) 15.50 [22.75] 7.50 [12.50] 7.00 [5.50] ※ 0.001
VAS 75.00 [13.80] 75.00 [15.00] 80.00 [10.00] ※# 0.005
ΔVAS 32.50 [55.00] 60.00 [21.30] 65.00 [16.30] ※ <0.001
FENO (ppb) 19.50 [17.00] 26.50 [23.00] 33.00 [32.25] ※ 0.008
WBC (*109/L) 6.04 [2.78] 6.29 [2.37] 6.73 [2.06] 0.714
EOS% 2.00 [1.90] 1.80 [1.43] 1.95 [2.55] 0.817
EOS (*109/L) 0.12 [0.13] 0.12 [0.08] 0.13 [0.20] 0.826
FVC%pred 98.81 [16.18] 99.39 [11.23] 93.09 [14.30] ※ 0.033
FEV1%pred 97.00 [14.78] 96.90 [17.09] 87.05 [17.42] ※# 0.001
FEV1/FVC 0.82 ± 0.06 0.81 ± 0.06 0.79 ± 0.05 0.06
PEF%pred$ 97.97 ± 15.61 95.18 ± 11.54 86.33 ± 18.68 ※# 0.001
FEF25%pred$ 97.34 ± 19.76 92.81 ± 15.97 81.58 ± 18.00 ※# <0.001
FEF50%pred$ 79.91 ± 22.96 80.45 ± 21.84 63.22 ± 14.19 ※# <0.001
FEF75%pred 62.01 [31.76] 65.60 [40.47] 49.96 [33.97] ※# 0.01
FEF25–75%pred$ 74.55 ± 22.06 77.41 ± 21.99 59.63 ± 16.91 ※# <0.001
Improvement-FVC 115.00 [235.00] 230.00 [172.50] † 390.00 [315.00] ※# <0.001
Improvement-FEV1 95.00 [90.00] 280.00 [92.50] † 480.00 [195.00]※# <0.001
Improvement- FEV1/FVC 0.00 [0.05] 0.02 [0.03] † 0.05 [0.06] ※ <0.001
Improvement-PEF -70.00 [1227.50] 150.00 [1365.00] 710.00 [1295.00] ※ <0.001
Improvement-FEF25 135.00 [1117.50] 485.00 [1050.00] † 1140.00 [1610.00] ※# <0.001
Improvement-FEF50 215.00 [552.50] 765.00 [615.00]† 930.00 [935.00] ※ <0.001
Improvement-FEF75 50.00 [460.00] 315.00 [377.50]† 410.00 [465.00] ※ <0.001
Improvement-FEF25–75 240.00 [515.00] 620.00 [480.00] † 905.00 [672.50] ※ <0.001
Improvement-FVC 4.14 [7.31] 5.86 [4.66] 11.16 [9.14] ※# <0.001
Improvement-FEV1% 3.97 [4.18] 9.46 [2.83] † 18.00 [5.45] ※# <0.001
Improvement-PEF% -1.18 [22.02] 2.32 [17.92] 14.05 [20.54] ※# <0.001
Improvement-FEF25% 1.18 ± 14.96 10.74 ± 14.44† 27.88 ± 25.39 ※# <0.001
Improvement-FEF50% 8.82 ± 18.26 24.20 ± 17.41† 39.26 ± 32.51 ※# <0.001
Improvement-FEF75% 5.86 [49.09] 14.30 [36.42] 45.73 [53.94] # <0.001
Improvement-FEF25–75% 8.45 [25.63] 22.24 [20.24] † 48.41 [31.62] ※# <0.001

Improvement-spirometric indices, increase in spirometric indices from baseline to 4 weeks of anti-asthma treatment. †, the difference between the negative group and the suspected group was statistically significant; ※, the difference between the negative group and positive group was statistically significant; #, the difference between the suspected group and positive group was statistically significant. The other abbreviations are as defined in Tables 1, 2. Statistical significance is shown by bold font.